DCTN4 and depressive symptom measurement: Further investigation of the 61 master hubs, especially those which are differentially expressed (C5AR1, CAVIN2, DCTN4, ETF1, GIMAP4-201, and NUDT21-201), may reveal novel therapeutic targets for psychiatric disorders, particularly depression, which represents the major portion of the clinical phenotype studied here.